In this letter, the authors suggest the possibility that α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor participates in the mediation of the increased brain-derived neurotrophic factor observed in chronic ketamine users. The fact that increased intracellular glutamate release may activate AMPA receptor and this, in turn, may upregulate BDNF gene expression is certainly a plausible hypothesis and is not in contrast with our interpretation. The authors themselves acknowledge that the possibility that glutamate activates AMPA [instead of N-methyl-D-aspartate (NMDA)] receptors is caused by (or linked to) ketamine's antagonist action at NMDA receptor which we proposed as the basic mechanism (Ricci et al. 2011) . The activation of AMPA receptors plasticity pathways has also been proposed to play a critical role in ketamine's rapid antidepressant effect. These rapid effects on depressive symptoms seem to take place through a direct trafficking of AMPA receptors (fast-acting ionic glutamaergic receptors) into the postsynaptic membrane (Machado-Vieira et al. 2009 ). Thus, we believe that the mechanism suggested by the authors is a valid compelling hypothesis to the interpretation of our data.
